Cancer Biomarkers
Genetic mutations, protein markers, and molecular targets that guide precision oncology treatment decisions.
Biomarkers
Cancer Biomarkers
- FeaturedALK
ALK
Anaplastic Lymphoma Kinase. Fusion driver in ~5% of NSCLC; targeted by alectinib, lorlatinib, brigatinib, ceritinib.
View Biomarker - Featured
BCMA
B-cell Maturation Antigen. Target of multiple myeloma CAR-T (idecabtagene vicleucel, ciltacabtagene autoleucel), bispecifics (teclistamab, elranatamab), and ADC (belantamab mafodotin).
View Biomarker - Featured
BCR-ABL
Philadelphia chromosome fusion gene defining CML and Ph+ ALL. Targeted by imatinib, dasatinib, nilotinib, ponatinib, asciminib.
View Biomarker - FeaturedBRAF
BRAF
Driver mutation in melanoma (50%), colorectal, thyroid, and lung cancers. BRAF V600E targeted by dabrafenib + trametinib and others.
View Biomarker - FeaturedBRCA1
BRCA1
Tumor suppressor gene; germline and somatic mutations confer sensitivity to PARP inhibitors. Important in breast, ovarian, prostate, pancreatic cancers.
View Biomarker - FeaturedBRCA2
BRCA2
Tumor suppressor gene; mutations confer sensitivity to PARP inhibitors and platinum-based chemotherapy.
View Biomarker - Featured
CD19
B-cell surface antigen targeted by approved CAR-T therapies (axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel) and bispecific antibody blinatumomab.
View Biomarker CD20
B-cell surface antigen targeted by rituximab, obinutuzumab, and bispecific antibodies (mosunetuzumab, glofitamab, epcoritamab).
View BiomarkerCD22
B-cell antigen targeted by inotuzumab ozogamicin (ADC) and emerging CD22 CAR-T therapies.
View BiomarkerCD33
Myeloid antigen targeted by gemtuzumab ozogamicin in AML.
View BiomarkerCD38
Plasma cell antigen targeted by daratumumab and isatuximab in multiple myeloma.
View BiomarkerCD7
T-cell antigen and target for emerging CAR-T therapies in T-ALL, including allogeneic approaches.
View Biomarker- FeaturedCLDN18
Claudin 18.2
Tight junction protein expressed in gastric and pancreatic cancers. Targeted by zolbetuximab (approved) and emerging CAR-T therapies including CT041 in China.
View Biomarker Del 17p
Deletion of 17p13 (TP53). High-risk feature in CLL and multiple myeloma; predicts resistance to chemotherapy.
View Biomarker- ESR1
ESR1
Estrogen receptor mutations driving endocrine resistance in metastatic breast cancer. Targeted by elacestrant and emerging SERDs.
View Biomarker - FGFR
FGFR
Fibroblast Growth Factor Receptor family. FGFR2 fusions in cholangiocarcinoma, FGFR3 mutations in bladder cancer. Targeted by pemigatinib, erdafitinib, infigratinib.
View Biomarker - FLT3
FLT3
FLT3-ITD and TKD mutations in AML. Targeted by midostaurin, gilteritinib, quizartinib.
View Biomarker - Featured
GD2
Disialoganglioside expressed in neuroblastoma and other tumors. Targeted by dinutuximab and naxitamab (approved); GD2 CAR-T in clinical trials.
View Biomarker GPRC5D
Plasma cell antigen targeted by talquetamab (bispecific) in relapsed/refractory multiple myeloma; emerging GPRC5D CAR-T trials.
View Biomarker- FeaturedERBB2
HER2
Human Epidermal Growth Factor Receptor 2. Overexpression in breast, gastric, esophageal cancers. Targeted by trastuzumab, pertuzumab, T-DM1, trastuzumab deruxtecan.
View Biomarker - IDH1
IDH1
Mutated in glioma, AML, cholangiocarcinoma. Targeted by ivosidenib.
View Biomarker - IDH2
IDH2
Mutated primarily in AML. Targeted by enasidenib.
View Biomarker - JAK2
JAK2
Driver mutation in myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, myelofibrosis). Targeted by ruxolitinib, fedratinib.
View Biomarker - FeaturedKRAS
KRAS
Most common oncogenic driver across solid tumors. KRAS G12C now targetable with sotorasib and adagrasib.
View Biomarker